calcipotriene and Carcinogenesis

The goal of field cancerization treatment is to reduce the risk of developing keratinocyte carcinoma. Selecting the appropriate therapy depends on the degree of field cancerization and the number of invasive cutaneous squamous cell carcinomas. Other considerations include treatment efficacy, cost, side effects, and patient preference. Field therapies are preferred because they address clinically visible disease and subclinical atypia. However, lesion-directed therapies are useful for lesions that are more difficult to treat or those where a histologic diagnosis is required. Patients with extensive field cancerization benefit from a combination of field-directed and lesion-directed treatments. The second article in this continuing medical education series provides a framework to guide evidence-based decision making for field cancerization treatment.

Topics: Administration, Cutaneous; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Carcinogenesis; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Decision-Making; Combined Modality Therapy; Cryosurgery; Dermatology; Drug Synergism; Evidence-Based Medicine; Fluorouracil; Humans; Injections, Intralesional; Keratosis, Actinic; Medical Oncology; Mohs Surgery; Neoplasms, Second Primary; Photochemotherapy; Randomized Controlled Trials as Topic; Skin; Skin Neoplasms; Skin Pigmentation; Treatment Outcome; Ultraviolet Rays